About Walvax Biotechnology Co., Ltd.
Walvax Biotechnology Co., Ltd. is a Chinese vaccine manufacturer founded in 2001 and headquartered in Kunming, Yunnan Province. Listed on the Shenzhen Stock Exchange since 2010 (300142), it researches, manufactures and distributes safe and efficacious vaccines, working to the stated purpose of helping everyone live a healthy life.
Its marketed portfolio includes the 13-valent pneumococcal conjugate vaccine, the recombinant bivalent human papillomavirus vaccine, the Haemophilus influenzae type b conjugate vaccine, the 23-valent pneumococcal polysaccharide vaccine and group A, C and ACYW135 meningococcal vaccines, plus a combined diphtheria, tetanus and acellular pertussis vaccine. Its largest manufacturing base is located in Yuxi, also in Yunnan.
According to its official English website, Walvax ranks among the world's top ten vaccine manufacturers by value (WHO Global Vaccine Market Report 2023, excluding COVID-19 vaccines), achieves full provincial coverage in China and exports its products to 26 countries, with registrations in progress in 20 more. It is a verifiable reference for buyers seeking a Chinese vaccine producer with an export track record.
Its marketed portfolio includes the 13-valent pneumococcal conjugate vaccine, the recombinant bivalent human papillomavirus vaccine, the Haemophilus influenzae type b conjugate vaccine, the 23-valent pneumococcal polysaccharide vaccine and group A, C and ACYW135 meningococcal vaccines, plus a combined diphtheria, tetanus and acellular pertussis vaccine. Its largest manufacturing base is located in Yuxi, also in Yunnan.
According to its official English website, Walvax ranks among the world's top ten vaccine manufacturers by value (WHO Global Vaccine Market Report 2023, excluding COVID-19 vaccines), achieves full provincial coverage in China and exports its products to 26 countries, with registrations in progress in 20 more. It is a verifiable reference for buyers seeking a Chinese vaccine producer with an export track record.